{"id":16028,"date":"2021-01-22T09:51:12","date_gmt":"2021-01-22T08:51:12","guid":{"rendered":"https:\/\/idibell.cat\/es\/?p=16028"},"modified":"2021-01-22T09:51:35","modified_gmt":"2021-01-22T08:51:35","slug":"aptadel-nueva-spinoff-del-idibell","status":"publish","type":"post","link":"https:\/\/idibell.cat\/es\/2021\/01\/aptadel-nueva-spinoff-del-idibell\/","title":{"rendered":"Aptadel, nueva spinoff del IDIBELL"},"content":{"rendered":"<p><strong>Aptadel Therapeutics<\/strong> es una empresa precl\u00ednica cofundada por el IDIBELL enfocada a desarrollar una nueva plataforma de terapia dirigida contra el c\u00e1ncer. Esta plataforma consiste en nanopart\u00edculas cargadas con agentes terap\u00e9uticos, como pueden ser mol\u00e9culas de ARN o f\u00e1rmacos quimioter\u00e1picos, dirigidas a diferentes tumores diana. De esta manera los agentes terap\u00e9uticos son liberados all\u00ed donde hace falta, evitando as\u00ed efectos secundarios y mejorando la efectividad de las terapias.<\/p>\n<p>El <strong>Dr. \u00d3scar Mart\u00ednez-Tirado<\/strong>, investigador del IDIBELL y cofundador de la spin-off, apunta que \u00abe<em>sta es una gran oportunidad para trasladar el conocimiento acad\u00e9mico a la pr\u00e1ctica cl\u00ednica<\/em>\u00ab. El Dr. Martinez-Tirado tiene a\u00f1os de experiencia en la investigaci\u00f3n del <strong>Sarcoma de Ewing<\/strong>, con esta nueva tecnolog\u00eda pretende administrar ARN de interferencia en las c\u00e9lulas tumorales que expresen EWS\/FLI1, el oncog\u00e9n responsable del desarrollo de estos tumores.<\/p>\n<p>Aptadel se lanza con una financiaci\u00f3n inicial de <strong>1,7 millones de euros<\/strong> resultado de una ronda de inversi\u00f3n iniciada por el IDIBELL. Los co-fundadores Fundaci\u00f3n Alba P\u00e9rez han aportado un fuerte conjunto de inversores privados que permitir\u00e1n a Aptadel desarrollar esta nueva tecnolog\u00eda para tratar diferentes tipos de c\u00e1ncer, pero que en un inicio se centrar\u00e1 en el Sarcoma de Ewing.<\/p>\n<p>&nbsp;<\/p>\n<p><em>El Instituto de Investigaci\u00f3n Biom\u00e9dica de Bellvitge (IDIBELL) es un centro de investigaci\u00f3n en biomedicina creado en 2004. Est\u00e1 participado por el Hospital Universitario de Bellvitge y el Hospital de Viladecans del Instituto Catal\u00e1n de la Salud, el Instituto Catal\u00e1n de Oncolog\u00eda, la Universidad de Barcelona y el Ayuntamiento de L&#8217;Hospitalet de Llobregat.<\/em><\/p>\n<p><em>El IDIBELL es miembro del Campus de Excelencia Internacional de la Universidad de Barcelona HUBc y forma parte de la instituci\u00f3n CERCA de la Generalitat de Catalunya. En 2009 se convirti\u00f3 en uno de los cinco primeros centros de investigaci\u00f3n espa\u00f1oles acreditados como instituto de investigaci\u00f3n sanitaria por el Instituto de Salud Carlos III. Adem\u00e1s, forma parte del programa \u00abHR Excellence in Research\u00bb de la Uni\u00f3n Europea y es miembro de EATRIS y REGIC. Desde el a\u00f1o 2018, IDIBELL es un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><em>Imagen: de izquierda a derecha, Maria del Pilar Gonz\u00e1lvez Pascual y, Rafael P\u00e9rez (por parte de la Fundaci\u00f3n Alba P\u00e9rez) y los doctores Gabriel Capell\u00e0 y Oscar Mart\u00ednez Tirado por parte de Aptade Therapeutics. (credito: Fundaci\u00f3 Alba P\u00e9rez)<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aptadel Therapeutics es una empresa precl\u00ednica cofundada por el IDIBELL enfocada a desarrollar una nueva plataforma de terapia dirigida contra el c\u00e1ncer.<\/p>\n","protected":false},"author":8,"featured_media":16029,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[184,281,241],"tags":[],"class_list":["post-16028","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-area-cancer","category-programa-de-mecanismos-moleculares-y-terapia-experimental-en-oncologia-oncobell","category-sarcoma"],"publishpress_future_action":{"enabled":false,"date":"2024-11-28 22:09:17","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/16028","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/comments?post=16028"}],"version-history":[{"count":0,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/posts\/16028\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media\/16029"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/media?parent=16028"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/categories?post=16028"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/es\/wp-json\/wp\/v2\/tags?post=16028"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}